These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 22142620)

  • 21. The editor's roundtable: the JUPITER trial--initial results and clinical implications.
    Ridker PM; Friedewald VE; Davidson MH; Willerson JT; Roberts WC
    Am J Cardiol; 2009 May; 103(10):1417-25. PubMed ID: 19427439
    [No Abstract]   [Full Text] [Related]  

  • 22. The cost-effectiveness of rosuvastatin therapy JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Hlatky M
    J Am Coll Cardiol; 2011 Feb; 57(7):792-3. PubMed ID: 21310314
    [No Abstract]   [Full Text] [Related]  

  • 23. HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
    Ridker PM; Genest J; Boekholdt SM; Libby P; Gotto AM; Nordestgaard BG; Mora S; MacFadyen JG; Glynn RJ; Kastelein JJ;
    Lancet; 2010 Jul; 376(9738):333-9. PubMed ID: 20655105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cholesterol lowering, cardiovascular diseases, and the rosuvastatin-JUPITER controversy: a critical reappraisal.
    de Lorgeril M; Salen P; Abramson J; Dodin S; Hamazaki T; Kostucki W; Okuyama H; Pavy B; Rabaeus M
    Arch Intern Med; 2010 Jun; 170(12):1032-6. PubMed ID: 20585068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
    Scheen AJ
    Rev Med Liege; 2008 Dec; 63(12):749-53. PubMed ID: 19180837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [JUPITER, what now?].
    Perna GP
    G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):33S-38S. PubMed ID: 21298860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
    Ridker PM;
    Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996
    [No Abstract]   [Full Text] [Related]  

  • 28. The numbers are in: statins for the primary prevention of cardiovascular disease in women.
    Duvernoy CS; Blumenthal R
    Circulation; 2010 Mar; 121(9):1063-5. PubMed ID: 20176993
    [No Abstract]   [Full Text] [Related]  

  • 29. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
    Ohsfeldt RL; Olsson AG; Jensen MM; Gandhi SK; Paulsson T
    J Med Econ; 2012; 15(1):125-33. PubMed ID: 22050473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinesin-like protein 6 (KIF6) polymorphism and the efficacy of rosuvastatin in primary prevention.
    Ridker PM; MacFadyen JG; Glynn RJ; Chasman DI
    Circ Cardiovasc Genet; 2011 Jun; 4(3):312-7. PubMed ID: 21493817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
    Albert MA; Glynn RJ; Fonseca FA; Lorenzatti AJ; Ferdinand KC; MacFadyen JG; Ridker PM
    Am Heart J; 2011 Jul; 162(1):106-14.e2. PubMed ID: 21742096
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The JUPITER trial: a new approach in primary prevention].
    Güleç S
    Turk Kardiyol Dern Ars; 2009 Apr; 37 Suppl 4():18-26. PubMed ID: 19553758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises?
    Efthimiadis A
    Angiology; 2008; 59(2 Suppl):62S-4S. PubMed ID: 18628276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).
    Everett BM; Glynn RJ; MacFadyen JG; Ridker PM
    Circulation; 2010 Jan; 121(1):143-50. PubMed ID: 20026779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
    Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096
    [No Abstract]   [Full Text] [Related]  

  • 36. Impact of the JUPITER trial on statin prescribing for primary prevention.
    Teng JF; Gomes T; Camacho X; Grundy S; Juurlink DN; Mamdani MM
    Pharmacotherapy; 2014 Jan; 34(1):9-18. PubMed ID: 23940007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA.
    Barrios V; Escobar C
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1317-27. PubMed ID: 19900015
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rosuvastatin outcomes study JUPITER closes early due to evidence of benefit.
    Cardiovasc J Afr; 2008; 19(2):117. PubMed ID: 18516361
    [No Abstract]   [Full Text] [Related]  

  • 40. [The JUPITER study: background and research hypotheses].
    Rapezzi C; Gallo P
    G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):25S-27S. PubMed ID: 21298858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.